Pitcairn Co. lessened its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 3.8% during the 4th quarter, Holdings Channel reports. The fund owned 16,400 shares of the conglomerate’s stock after selling 656 shares during the period. Pitcairn Co.’s holdings in Danaher were worth $3,765,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Gilbert & Cook Inc. raised its holdings in shares of Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock worth $401,000 after buying an additional 42 shares during the last quarter. Grimes & Company Inc. increased its stake in shares of Danaher by 0.6% in the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after purchasing an additional 43 shares in the last quarter. Dakota Community Bank & Trust NA raised its stake in shares of Danaher by 16.4% during the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after buying an additional 45 shares during the period. Howard Capital Management Group LLC lifted its holdings in Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 48 shares in the last quarter. Finally, Spinnaker Trust lifted its stake in Danaher by 1.2% in the 4th quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock valued at $988,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Activity
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 11.10% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on DHR
Danaher Trading Up 2.4 %
Shares of NYSE DHR opened at $205.23 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $196.34 and a 12 month high of $281.70. The company has a market cap of $146.68 billion, a price-to-earnings ratio of 38.87, a P/E/G ratio of 2.66 and a beta of 0.86. The business has a fifty day simple moving average of $212.24 and a 200-day simple moving average of $235.18.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm posted $2.09 earnings per share. Sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.62%. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio is presently 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- Dividend Payout Ratio Calculator
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Calculate Stock Profit
- The 3 Most Talked About Investments on WallStreetBets Right Now
- EV Stocks and How to Profit from Them
- Analyst Targets Signal More Growth in CrowdStrike Stock
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.